FDA Clears Brain MRI-Based Software for Assessing Cortical Disarray Measurement
The CDM Insights software, which can be utilized with scans from 1.5T and 3T MRI, reportedly provides new measurements of cortical thickness and brain microstructure.
The Food and Drug Administration (FDA) has granted 510(k) clearance for CDM Insights, a magnetic resonance imaging (MRI)-based software that may facilitate early detection of neurodegeneration.
The cloud-native CDM (Cortical Disarray Measurement) Insights software enables neuroradiologists to assess new measurements of brain microstructure and cortical thickness that were previously unavailable in the United States, according to Oxford Brian Diagnostics, the developer of the CDM Insights software.
For the assessment of brain MRI, the newly FDA-cleared CDM Insights software provides neuroradiologists with new measurements of brain microstructure and cortical thickness that were previously unavailable in the United States, according to Oxford Brain Diagnostics, the developer of CDM Insights. (Image courtesy of Adobe Stock.)
"Our technology empowers clinicians with the tools they need to detect subtle brain changes and to diagnose with confidence at an early stage,” noted Steven Chance, Ph.D., the CEO and co-founder of Oxford Brian Diagnostics. “These insights also help patients gain a better understanding of the changes happening in their brains, addressing the uncertainty often experienced with the early signs of Alzheimer's disease. Ultimately, this enables providers … to understand patient brain structure changes prior to symptom progression and improve patient outcomes."
The company said CDM Insights allows clinicians to monitor brain changes across multiple stages of adult life and enables assessment of patients with neurodegenerative disorders such as Alzheimer’s disease. The software can be utilized with scans from 1.5T or 3T MRI devices, according to Oxford Brain Diagnostics.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
